Drug news
AstraZeneca to develop reversal agent MEDI 2452 for Brilinta
AstraZeneca has announced that it has begun a pre-clinical development programme to evaluate the ability of investigational antibody, MEDI 2452, to rapidly and specifically reverse the antiplatelet effects of Brilinta ( ticagrelor) in rare emergency situations such as urgent surgery, or in the event of major bleeding. MEDI 2452 is being developed by MedImmune, AstraZeneca�s biologics research and development arm.